Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial assessing CB-5339 in multiple myeloma

X
Trial Profile

A clinical trial assessing CB-5339 in multiple myeloma

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CB 5339 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Jul 2023 According to a CASI Pharmaceuticals media release, the company is planning to start this study in early 2023
    • 06 Jan 2023 According to a CASI Pharmaceuticals media release, the China National Medical Products Administration (NMPA) has approved this trial., and expected to begin in 2023.
    • 14 Nov 2022 According to a CASI Pharmaceuticals media release, company expect CB-5339 to receive Clinical Trial Application approval from the NMPA in early 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top